![]() |
Name |
[(2R,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] (E)-2-methylbut-2-enoate
|
Molecular Formula | C22H34O13 | |
IUPAC Name* |
[(2R,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] (E)-2-methylbut-2-enoate
|
|
SMILES |
C/C=C(/C(=O)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)OC(=O)/C(=C/C)/C)O)CO)O)\C
|
|
InChI |
InChI=1S/C22H34O13/c1-5-9(3)19(29)33-17-13(25)11(7-23)31-21(15(17)27)35-22-16(28)18(14(26)12(8-24)32-22)34-20(30)10(4)6-2/h5-6,11-18,21-28H,7-8H2,1-4H3/b9-5+,10-6+/t11-,12-,13-,14-,15-,16-,17+,18+,21-,22-/m1/s1
|
|
InChIKey |
GOCSEFUZLXEMPL-KTTJKFNESA-N
|
|
Synonyms |
Trehangelin A; J3.637.460H
|
|
CAS | NA | |
PubChem CID | 132508505 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 506.5 | ALogp: | -0.6 |
HBD: | 6 | HBA: | 13 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 202.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 35 | QED Weighted: | 0.16 |
Caco-2 Permeability: | -5.958 | MDCK Permeability: | 0.00022548 |
Pgp-inhibitor: | 0.025 | Pgp-substrate: | 0.994 |
Human Intestinal Absorption (HIA): | 0.94 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.997 |
Blood-Brain-Barrier Penetration (BBB): | 0.153 | Plasma Protein Binding (PPB): | 34.55% |
Volume Distribution (VD): | 0.53 | Fu: | 25.10% |
CYP1A2-inhibitor: | 0.036 | CYP1A2-substrate: | 0.036 |
CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.422 |
CYP2C9-inhibitor: | 0.004 | CYP2C9-substrate: | 0.077 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.064 |
CYP3A4-inhibitor: | 0.034 | CYP3A4-substrate: | 0.02 |
Clearance (CL): | 1.329 | Half-life (T1/2): | 0.776 |
hERG Blockers: | 0.088 | Human Hepatotoxicity (H-HT): | 0.658 |
Drug-inuced Liver Injury (DILI): | 0.624 | AMES Toxicity: | 0.147 |
Rat Oral Acute Toxicity: | 0.009 | Maximum Recommended Daily Dose: | 0.002 |
Skin Sensitization: | 0.256 | Carcinogencity: | 0.017 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.047 |
Respiratory Toxicity: | 0.021 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002949 | ![]() |
0.918 | D07BSE | ![]() |
0.382 | ||
ENC002950 | ![]() |
0.842 | D0T5BC | ![]() |
0.360 | ||
ENC0049112 | ![]() |
0.346 | D0YV1Q | ![]() |
0.351 | ||
ENC003351 | ![]() |
0.336 | D0D0SH | ![]() |
0.350 | ||
ENC002269 | ![]() |
0.325 | D02HYK | ![]() |
0.350 | ||
ENC003820 | ![]() |
0.324 | D0A8RX | ![]() |
0.346 | ||
ENC003819 | ![]() |
0.320 | D0Y3MO | ![]() |
0.333 | ||
ENC004854 | ![]() |
0.316 | D07QQD | ![]() |
0.332 | ||
ENC001939 | ![]() |
0.310 | D04NDM | ![]() |
0.329 | ||
ENC001938 | ![]() |
0.303 | D07BCT | ![]() |
0.326 |